Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen

Inclusion Criteria:

Patients must provide written consent to cooperate in this study before the start of treatment with Kesimpta

Patients using Kesimpta for the first time for the following indication Indication: prevention of relapses and and prevention of physical disability progression in the following patients

Relapsing-remitting MS
Active SPMS

Exclusion Criteria:

Patients with a history of treatment with a drug containing the same ingredient as Kesimpta (investigational drug or post-marketing clinical study drug)
Patients with a history of hypersensitivity to any of the Kesimpta ingredients